Efficient killing of tumor cells by CAR-T cells requires greater number of engaged CARs than TCRs.
T-cell bioengineering
T-cell receptor (TCR)
chimeric antigen receptor (CAR)
immunotherapy
killing efficiency of various melanoma cells by CAR- or TCR-triggered T-cells
receptor regulation
tumor immunology
Journal
The Journal of biological chemistry
ISSN: 1083-351X
Titre abrégé: J Biol Chem
Pays: United States
ID NLM: 2985121R
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
received:
20
12
2020
revised:
28
07
2021
accepted:
29
07
2021
pubmed:
10
8
2021
medline:
15
12
2021
entrez:
9
8
2021
Statut:
ppublish
Résumé
Although CAR-T cells are widely used to treat cancer, efficiency of CAR-T cell cytolytic responses has not been carefully examined. We engineered CAR specific for HMW-MAA (high-molecular-weight melanoma-associated antigen) and evaluated potency of CD8+ CAR-T cells to release cytolytic granules and to kill tissue-derived melanoma cells, which express different levels of HMW-MAA. CAR-T cells efficiently killed melanoma cells expressing high level of HMW-MAA, but not melanoma cells with lower levels of HMW-MAA. The same melanoma cells presenting significantly lower level of stimulatory peptide-MHC ligand were readily lysed by T cells transduced with genes encoding α,β-TCR specific for the peptide-MHC ligand. The data suggest that higher level of targeted molecules is required to engage a larger number of CARs than TCRs to induce efficient cytolytic granule release and destruction of melanoma cells. Understanding the difference in molecular mechanisms controlling activation thresholds of CAR- versus TCR-mediated responses will contribute to improving efficiency of CAR T cells required to eliminate solid tumors presenting low levels of targeted molecules.
Identifiants
pubmed: 34371020
pii: S0021-9258(21)00835-8
doi: 10.1016/j.jbc.2021.101033
pmc: PMC8452787
pii:
doi:
Substances chimiques
Antigens, Neoplasm
0
HLA-A2 Antigen
0
HMW-MAA
0
Receptors, Antigen, T-Cell
0
Receptors, Chimeric Antigen
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
101033Informations de copyright
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict of interest The authors declare that they have no conflicts of interest with the contents of this article.